A panel of the US Centers for Disease Control and Prevention (CDC) has voted 12-0 that Johnson & Johnson's COVID-19 vaccine should be used to inoculate adults 18 years old and older, as reported in Yahoo!Finance.
The CDC's Advisory Committee on Immunization Practices (ACIP) held an emergency meeting Sunday to review candidate, which the FDA authorised for emergency use the day before.
Members of the committee generally had favorable comments about the vaccine, but one concern was that it appeared to be less effective among people age 60 and older who had co-morbidities.
Macaya Douoguih, head of clinical development and medical affairs with Johnson & Johnson's Janssen unit, said those results should be interpreted with caution because they are based on a relatively small number of COVID-19 cases in that subgroup.
The vaccine can be administered once the CDC finalises its guidelines, with the first doses slated to be distributed this week. It is expected CDC director Rochelle Walensky will sign off on the ACIP recommendation imminently.
Meanwhile, Jason Goldman, a representative of the American College of Physicians, stressed the importance of discouraging comparisons among the three available COVID-19 vaccines – Pfizer and Moderna's products being the other two. "We want to make sure that the public understands the best vaccine is the one they can get access to," said Goldman, a liaison to the panel.
To read more NewsPoints articles, click here.